DRUG METABOLISM & DISPOSITION

Special Section on New Era of Transporter Science: Unraveling the Functional Role of Orphan Transporters—Minireview

Clinical Applications and the Roles of Transporters in Disposition, Tumor Targeting, and Tissue Toxicity of *meta*-Iodobenzylguanidine

Antonio J. López Quiñones, Letícia Salvador Vieira, and Joanne Wang

Department of Pharmaceutics, University of Washington, Seattle, Washington

ABSTRACT

Transporters on the plasma membrane of tumor cells are promising molecular "Trojan horses" to deliver drugs and imaging agents into cancer cells. Radioiodine-labeled *meta*-iodobenzylguanidine (mIBG) is used as a diagnostic agent (^{123}I-mIBG) and a targeted radiotherapy (^{131}I-mIBG) for neuroendocrine cancers. mIBG enters cancer cells through the norepinephrine transporter (NET) where the radioactive decay of ^{131}I causes DNA damage, cell death, and tumor necrosis. mIBG is predominantly eliminated unchanged by the kidney. Despite its selective uptake by neuroendocrine tumors, mIBG accumulates in several normal tissues and leads to tissue-specific radiation toxicities. Emerging evidences suggest that the polyspecific organic cation transporters play important roles in systemic disposition and tissue-specific uptake of mIBG. In particular, human organic cation transporter 2 (hOCT2) and multidrug and toxin extrusion proteins 1 and 2-K (hMATE1/2-K) likely mediate renal secretion of mIBG, whereas hOCT1 and hOCT3 may contribute to mIBG uptake into normal tissues such as the liver, salivary glands, and heart. This mini-review focuses on the clinical applications of mIBG in neuroendocrine cancers and the differential roles of NET, OCT, and MATE transporters in mIBG disposition, response and toxicity. Understanding the molecular mechanisms governing mIBG transport in cancer and normal cells is a critical step for developing strategies to optimize the efficacy of ^{131}I-mIBG while minimizing toxicity in normal tissues.

SIGNIFICANCE STATEMENT

Radiolabeled *meta*-iodobenzylguanidine (mIBG) has been used as a diagnostic tool and as radiotherapy for neuroendocrine cancers and other diseases. Norepinephrine transporter, organic cation transporters, and multidrug and toxin extrusion proteins play differential roles in tumor targeting, systemic elimination, and accumulation in normal tissues. The clinical use of mIBG as a radiopharmaceutical in cancer diagnosis and treatment can be further improved by taking a holistic approach considering mIBG transporters in both cancer and normal tissues.

Introduction

Cancer continues to be a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020 (Ferlay et al., 2020). Precise detection and diagnosis of specific tumor types and disease stages is essential for designing the appropriate and effective regimens for treatment. Further, cancer treatment often involves radiotherapy and chemotherapy, which not only kills cancer cells but also affects healthy cells. Treatment-related toxicity is frequently a dose-limiting factor and represents a major challenge in clinical management of cancer. Hence, a major goal in cancer drug development and therapy is to increase tumor-specific drug uptake while reducing uptake into normal tissues to minimize toxicities.

Transporters on the plasma membrane of tumor cells represent promising molecular "Trojan horses" to deliver drugs and imaging agents into cancer cells. Transporter-mediated uptake has been exploited successfully in nuclear medicine to deliver several radiopharmaceuticals for cancer imaging and treatment (Zhang and Wang, 2020). For instance, the use of ^{131}I radiotherapy to treat thyroid cancer is highly dependent on the selective expression of the sodium/iodine symporter on these cells (Kogai and Brent, 2012). The use of ^{18}F fluorodeoxyglucose (^{18}F-FDG) as a cancer imaging agent is due to the Warburg effect and glucose transporter 1-mediated uptake in rapidly growing tumor cells (Ancey et al., 2018; Zhang and Wang, 2020). Radiolabeled *meta*-iodobenzylguanidine (mIBG) is designed to target the norepinephrine transporter (NET), which is highly expressed in neuroendocrine tumors (DuBois et al., 2012; Streby et al., 2015; Zhang and Wang, 2020). Despite its selective uptake by cancer cells, mIBG also accumulates in several normal tissues such as liver, heart, salivary glands, and intestines and leads to tissue-specific radiation toxicities (Matthay et al., 2006; Bleeker et al., 2013; Parisi et al., 2016; Pryma et al., 2019). Emerging evidences suggest that the polyspecific organic cation

---

ABBREVIATIONS: FDA, US Food and Drug Administration; HDAC, histone deacetylase; Km, apparent affinity; MATE, multidrug and toxin extrusion protein; mIBG, *meta*-iodobenzylguanidine; MRP, multidrug resistance protein; NET, norepinephrine transporter; OCT, organic cation transporter; PMAT, plasma membrane monoamine transporter; SERT, serotonin transporter; SPECT, single photon emission computed tomography; VMAT, vesicular monoamine transporter.

Fig. 1. Chemical structure of mIBG and compounds that inspired the development of benzylguanidines. The red circle indicates the position of ^{123}I or ^{131}I labeling on mIBG.

transporters are the major transporters driving the systemic elimination and tissue-specific disposition of mIBG in normal organs. In this review, we focus on the clinical pharmacology of mIBG and the impact of transporters on mIBG disposition in both tumor and normal cells. It is hoped that through analyzing the case of mIBG, much can be learned about the challenges and opportunities of targeting membrane transporters in cancer diagnosis and treatment.

History and Development of mIBG

Historically, mIBG is a structural analog of norepinephrine (Fig. 1) and was first developed as a noninvasive imaging agent to detect and characterize irregularities in the adrenal glands. The adrenal gland is comprised of two embryologically distinct tissues, the cortex and medulla (Willenberg and Bornstein, 2017; Dutt et al., 2021). The cortex arises from the mesoderm and is involved in steroidogenesis. The medulla is derived from the neuroectoderm and is responsible for producing catecholamines (epinephrine, norepinephrine) involved in the "fight-or-flight" response. Early imaging efforts exploited the physiologic roles of these tissues through the use of radioiodinated cholesterols and radiolabeled catecholamines that can accumulate in the adrenal system (Fowler et al., 1973; Beierwaltes et al., 1978). Since the adrenal medulla functions like a specialized sympathetic ganglion, compounds with an affinity for adrenergic nerves would be expected to accumulate in the adrenal system. In the early 1960s, two antihypertensive drugs, guanethidine and bretylium (Fig. 1), entered the US market and were potent and selective adrenergic blocking agents. This led to the development of benzylguanidines as potential antiadrenergic agents by combining the halogenated benzyl group of bretylium and the guanidine group in guanethidine (Short and Darby, 1967).

In the late 1970s, Dr. Beierwaltes' group at the University of Michigan set out to develop a radiopharmaceutical that could image the adrenal medulla and its neoplasms (Wieland et al., 1980). They radiolabeled the benzylguanidines with ^{131}I and investigated their accumulation in the adrenal glands and other tissues. It was found that *para*-iodobenzylguanidine (pIBG) and *meta*-iodobenzylguanidine (mIBG) were highly concentrated in the adrenal glands of dogs for up to 192 hours. The compounds also accumulated in other tissues (e.g., liver, kidney, heart, and lung) but their concentrations decreased over time with minimal to no radiation after 48 hours. Although pIBG had greater accumulation in

the adrenal glands, mIBG was shown to have less accumulation in the thyroid gland, have less in vivo deiodination, and be more metabolically stable (Wieland et al., 1980, 1984). Therefore, mIBG was selected for further development as a diagnostic imaging agent for the adrenal medulla and related cancers.

After its success in multiple imaging studies and shown to be safe following intravenous administration, ^{131}I-mIBG (iobenguane) was approved by the US Food and Drug Administration (FDA) in 1994 to diagnose neuroendocrine cancers. However, there are limitations to the use of ^{131}I-mIBG as an imaging agent. The conventional gamma camera inefficiently captures the principal photon (364 keV) emitted by the radioactive decay of the ^{131}I isotope, leading to scatter and image noise (Liu et al., 2013). In addition, 90% of radioactive decay for the ^{131}I isotope is via β-emission, and its decay half-life (8 days) does not contribute to favorable image formation. In contrast, the principal photon of the ^{123}I isotope (159 keV) is more suited for imaging with conventional gamma cameras and has a relatively shorter decay half-life (13 hours) compared with [131]I. The improved image resolution, better dosimetric profile, and single photon emission computed tomography (SPECT) capabilities led to FDA approval of ^{123}I-mIBG (AdreView) in 2008.

Due to its adrenergic imaging capabilities, ^{123}I-mIBG has also been successfully applied for cardiac imaging and was approved by the FDA in 2013 to image the sympathetic innervation of the myocardium. In addition, due to its selective accumulation in neuroendocrine tumor cells, mIBG was tested as a targeted radiotherapy to treat several neuroendocrine cancers (Parisi et al., 2016; Pryma et al., 2019). In this case, the β emission by ^{131}I is more favorable than ^{123}I, as the stronger radiation emission can penetrate surrounding cancer cells and result in DNA damage and cell death. High dose ^{131}I-mIBG (Azedra; Progenics Pharmaceuticals, Inc., New York, NY) was approved by the FDA in 2018 and proved efficacious in the treatment of advanced pheochromocytoma and paraganglioma. Lastly, ^{131}I-mIBG is under investigation in multiple clinical trials for the treatment of neuroblastoma (Parisi et al., 2016; DuBois et al., 2021).

Clinical Uses of mIBG

Neuroblastoma. Neuroblastoma is the most common extracranial solid tumor in children and accounts for over 15% of all pediatric cancer mortalities in the US (Maris et al., 2007). Most patients are

diagnosed at infancy, with a median age at diagnosis of 19 months (Ward et al., 2014). Neuroblastoma is a malignancy of the sympathoadrenal lineage of the neural crest cells and can arise anywhere in the sympathetic nervous system. Approximately 70% of primary tumors occur within the abdominal region, with at least half of the primary tumors arising in the adrenal gland. Unfortunately, approximately half of the patients are metastatic at diagnosis, most commonly to the bone and bone marrow, lymph nodes, and liver (DuBois et al., 1999).

Neuroblastoma is heterogenous in its clinical presentation and can spontaneously regress or progress as an aggressive metastatic cancer. Patients with neuroblastoma are stratified as low, intermediate, or high-risk based on age, tumor stage, and biologic factors, and the classification affects prognosis and treatment strategies (Park et al., 2008). Low- and intermediate-risk patients undergo surgery and/or chemotherapy with survival rates of greater than 90% (Irwin and Park, 2015). In contrast, high-risk neuroblastoma patients undergo a combination of surgery, autologous transplantation, chemotherapy, and whole-body radiation with survival rates of less than 40%–50% (Matthay et al., 1999; Parisi et al., 2016).

[123]I-mIBG is routinely used in the clinic to diagnose neuroblastoma by detecting primary tumors and to identify sites of metastasis (Matthay et al., 2010). In a cohort of 66 confirmed neuroblastoma cases, ^{123}I-mIBG scintigraphy had a sensitivity of 88% and specificity of 83% for diagnosing neuroblastoma (Vik et al., 2009). When combined with planar and SPECT imaging, the sensitivity rose to 91%. With the inclusion of histopathology information, the sensitivity and specificity rose to 93% and 92%, respectively (Vik et al., 2009). Of note, false positive interpretations in this cohort were due to atypical adrenal or normal tissue uptake. Another study had similar results, with false negative rates of approximately 8% in 196 patients with pathologically proven neuroblastoma (Biasotti et al., 2000). Patients with bone metastasis at diagnosis had increased false negative rates of up to 21% without additional diagnostic tests (Gordon et al., 1990). Nevertheless, ^{123}I-mIBG scintigraphy has proven to be an essential imaging agent for diagnosing and monitoring disease progression of neuroblastoma.

The use of ^{131}I-mIBG as a therapeutic agent began in the early 1980s and was predominantly focused on the treatment of relapsed or refractory neuroblastoma (Treuner et al., 1988). Subsequently, multiple strategies have been undertaken to improve the clinical outcomes of relapsed or refractory neuroblastoma. These strategies include: the use of ^{131}I-mIBG as a monotherapy, as a combination therapy with radiosensitizers, in conjunction with bone marrow transplantation, and as part of the induction therapy with concomitant chemotherapeutic regimens (Matthay et al., 1999; Johnson et al., 2011; DuBois et al., 2015; Yanik et al., 2015). These strategies have shown complete response rates similar to or better than the standard of care for high-risk neuroblastoma patients. Additionally, ^{131}I-mIBG has been investigated as a front-line treatment of patients with neuroblastoma and has shown a response rate of up to 73%, higher than the typical response for high-risk patients (de Kraker et al., 2008).

Toxicity is a major concern for ^{131}I-mIBG therapy. Toxicities are associated with the radioactive ^{131}I whereas nonradiolabeled mIBG is nontoxic. Hematologic toxicities are the most common and severe toxicities, but patients are rescued by autologous stem cell infusion (Bleeker et al., 2013). Thyroid uptake of [123/131]I-mIBG is usually blocked by coadministration with potassium iodine or Lugol's solution to saturate the sodium-iodine symporter (Matthay et al., 2007; Parisi et al., 2016). However, radiation to the thyroid is still observed in patients and can lead to hypothyroidism months after treatment (Van Santen et al., 2002). Transient cardiac toxicities can occur during ^{131}I-mIBG infusion and require continuous and automated blood pressure monitoring (Parisi et al., 2016). Tachycardia and hypertension are the most common cardiac toxicities in patients with neuroblastoma and occur in approximately 10% of neuroblastoma patients receiving ^{131}I-mIBG therapy (Shusterman et al., 2011). Other significant toxicities include gastrointestinal disturbances (nausea, vomiting), sialadenitis (swelling of the salivary glands), and hepatic-related toxicities (Bleeker et al., 2013; Parisi et al., 2016). When ^{131}I-mIBG is used in combination with other anticancer drugs, improvements to the response rates are variable and the ^{131}I-mIBG associated toxicities can be exacerbated (Matthay et al., 2006).

Pheochromocytoma and Paraganglioma. In addition to neuroblastoma, ^{123}I-mIBG has been successfully used in the localization and evaluation of other neuroendocrine cancers, in particular pheochromocytoma and paraganglioma. Unlike neuroblastoma, sporadic forms of pheochromocytoma and paraganglioma are usually diagnosed in individuals aged 40–50 years and are rare in children (Neumann et al., 1993). Pheochromocytoma and paraganglioma arise from the chromaffin cells that produce catecholamines in the adrenal medulla or accessory adrenal tissue (Lenders et al., 2005). The two tumor types cannot be differentiated based on histology alone; hence, anatomic location of the tumors is used to distinguish between them (Lam, 2017). Based on the 2017 World Health Organization (WHO) classification, pheochromocytoma is an adrenal tumor, whereas paraganglioma is an extra-adrenal tumor. Approximately 80% of patients with pheochromocytoma present with primary tumors in the adrenal medulla and frequently produce excessive levels of catecholamines (Eisenhofer et al., 2003). The rest of primary tumors are typically localized in the paravertebral sympathetic ganglia of the abdominal region and typically do not present with hypersecretion of catecholamines. Pheochromocytoma and paraganglioma are both rare cancers with a prevalence of 0.3% in patients with hypertension (Anderson et al., 1994). However, fatal complications preceded diagnosis in a significant proportion of patients with pheochromocytoma, as evidenced in over 8000 autopsies, indicating that the cancer is often undetected and left untreated (Lo et al., 2000).

[123]I-mIBG scintigraphic imaging has been proved to successfully help diagnose pheochromocytoma. ^{123}I-mIBG SPECT imaging has a reported sensitivity of 83%–100% and a specificity of 95%–100% for detecting pheochromocytomas (Nielsen et al., 1996). However, ^{123}I-mIBG has a lower sensitivity (56%–75%) for detecting the extra-adrenal paragangliomas and in patients with genetic mutations of succinate dehydrogenase, an enzyme involved in the Krebs cycle and associated with metastasis (Wiseman et al., 2009). Nonetheless, patients who exhibit positive ^{123}I-mIBG scintigraphy may benefit from ^{131}I-mIBG radiotherapy (Rao et al., 2019).

The goals for ^{131}I-mIBG as treatment of pheochromocytoma are focused on alleviating symptoms, lowering blood pressure, reducing catecholamine secretion, and ultimately shrinking tumors with minimal systemic toxicity (Beierwaltes, 1987). The early noncontrolled clinical trials with ^{131}I-mIBG for treating pheochromocytoma failed to achieve complete remission in most patients but produced an improvement in sustained remission or stable disease for up to 2 years (Loh et al., 1997). More recent studies have used ^{131}I-mIBG therapy in patients with predominantly nonresectable and malignant pheochromocytoma and paraganglioma (Kotecka-Blicharz et al., 2018; Pryma et al., 2019; Wakabayashi et al., 2019). These studies showed high rates of stable disease in patients treated with ^{131}I-mIBG therapy and a significant reduction in the use of hypertension medication. In addition, the use of ^{131}I-mIBG therapy to reduce tumor size prior to surgery in a case study of two patients highlighted the potential of ^{131}I-mIBG as an adjunctive therapy with surgery for pheochromocytoma (Dhingra and Halkar, 2020). The toxicities in pheochromocytoma patients given ^{131}I-mIBG were similar to those in neuroblastoma patients, with hematologic

toxicities being the most common and reported hypothyroidism, hypertension, dry mouth, and gastrointestinal disturbances.

Pharmacokinetics of mIBG

mIBG is administered as an intravenous infusion over 1–2 minutes for ^{123}I-mIBG diagnostic imaging and 60–120 minutes for ^{131}I-mIBG radiotherapy (Parisi et al., 2016). The blood concentrations of mIBG rapidly decrease in a biphasic manner with a half-life of the initial phase of approximately 0.2–0.3 hours and a long terminal half-life greater than 38 hours (Coleman et al., 2009; Chin et al., 2014). The amount of mIBG in the blood after 5 minutes corresponds to about 10% of the dose. mIBG has a large volume of distribution of 3–5 l/kg, indicating a substantial distribution into tissues. After 1 hour, only 2%–4% of the dose remains within the vascular compartment.

The systemic elimination pathways of mIBG are summarized in Fig. 2. The majority (>90%) of the administered dose is excreted into the urine unchanged, with 50% of the dose excreted into the urine within 24 hours (Lashford et al., 1988; Blake et al., 1989; Parisi et al., 2016). Both glomerular filtration and tubular secretion are involved in mIBG elimination by the kidney (Ehninger et al., 1987; López Quiñones et al., 2020). Fecal excretion accounts for less than 1% of the total mIBG dose, whereas dissociation of the ^{123}I/^{131}I from mIBG accounts for less than 5% of the total dose. Metabolism of mIBG accounts for less than 10% of the dose, with the major metabolite being meta-iodohippuric acid (Mangner et al., 1986; Coleman et al., 2009; Chin et al., 2014).

mIBG exhibits extensive physiologic distribution into normal tissues. Based on whole-body scintigraphy scans, mIBG distributes and accumulates in the salivary glands, liver, intestines, thyroid, lungs, spleen, muscle, urinary bladder, and adrenal glands (Nakajo et al., 1983; Coleman et al., 2009; Chin et al., 2014). The salivary glands, a highly sympathetically innervated tissue, exhibit the highest radiation exposure of mIBG and can consistently be visualized in scintigraphic images. The tissue distribution and accumulation are similar between ^{123}I-mIBG and ^{131}I-mIBG (Nakajo et al., 1983; Parisi et al., 1992).

mIBG Disposition in Cancer Cells and the Role of NET

The broad clinical applications of radioiodinated mIBG are due to its structural similarities to norepinephrine (Fig. 1) and its active uptake by the Na$^+$-dependent norepinephrine transporter (NET; *SLC6A2*) expressed in neurons and neuroendocrine cancer cells (Streby et al., 2015). With a pKa of ~13, mIBG exists predominantly as a cation at physiologic pH. Although nonsaturable, passive transport has been suggested for mIBG; active transport is at least 50-fold more efficient than passive diffusion at lower mIBG concentrations (Mairs et al., 1995; Streby et al., 2015). Once inside the cells, the gamma radiation emitted by the radioactive isotope of iodine allows for imaging of the tumor and—in the case of [131]I—emission of beta particles can lead to DNA damage and cell death. Unlike norepinephrine, metabolism does not contribute to the elimination of mIBG in the neuroendocrine cells, as mIBG is not a substrate of monoamine oxidase (MAO) or catechol-O-methyltransferase (COMT) (Graefe et al., 1999). However, mIBG can be transported out of the cancer cells by efflux mechanisms. As the tumor killing efficiency is directly related to how much and how long the radioactive ^{131}I stays in cancer cells, tumor-selective uptake, retention, and efflux are the main determinants of the clinical efficacy of ^{131}I-mIBG.

Currently, it is believed that NET is the major transporter driving mIBG uptake into neuroendocrine cancer cells. NET is highly expressed in most neuroendocrine tumors derived from neural crest and chromaffin cells of the adrenal medulla (DuBois et al., 2012; Streby et al., 2015; Zhang and Wang, 2020). NET is expressed in ~90% neuroblastoma tumor samples, and its expression has been correlated with mIBG avidity in ^{123}I-mIBG imaging (Carlin et al., 2003; DuBois et al., 2012; Streby et al., 2015). Due to the major role NET has in mIBG uptake, drugs known to interfere with NET function such as tricyclic antidepressants and norepinephrine reuptake inhibitors (e.g., amitriptyline, bupropion, duloxetine, venlafaxine) should be discontinued during treatment with mIBG according to the Azedra (2018) (^{131}I-mIBG) drug label. Coadministration of such medications could lead to reduction in mIBG uptake in tumor tissue and therefore reduced efficacy and/or false negative imaging results. On the other hand, several studies have explored approaches aimed at enhancing NET expression in tumor cells with the goal of increasing ^{131}I-mIBG efficacy (More et al., 2011; DuBois et al., 2015; Streby et al., 2015). For instance, More et al. (2011) showed that vorinostat, a histone deacetylase (HDAC) inhibitor, increased tumor NET expression and mIBG uptake in preclinical models of neuroblastoma. The specific mechanism by which vorinostat upregulates NET expression has not been well defined but is thought to relate to its inhibitory effect on HDACs (More et al., 2011). HDACs can act as transcription repressors for some genes, and inhibition of HDACs could

Fig. 2. Elimination pathways of mIBG in humans. The majority of mIBG (>90% of administered dose) is excreted unchanged in urine. Other pathways such as fecal elimination, chemical degradation, and metabolism are minor routes in systemic elimination of mIBG.

Fig. 3. Proposed roles of transporters in tumor disposition, normal tissue disposition, and systemic elimination of mIBG. (A) In neuroendocrine tumors, mIBG uptake is mediated by NET. In pheochromocytoma and paraganglioma, uptake into storage vesicles by VMATs is believed to play a significant role in intracellular retention of mIBG. In neuroblastoma, however, most of mIBG is found in the cytoplasm and concentrates within the mitochondria through a currently unknown mechanism. Efflux by MRPs was suggested as a possible tumor efflux mechanism; however, clinical evidence of such is limited. (B) The polyspecific organic cation transporters OCT1–3 and MATE1/2-K are believed to play a role in normal tissue distribution and in systemic elimination of mIBG. Tissue expression pattern of such transporters indicates that OCT3 may be involved in mIBG accumulation in salivary glands and heart, whereas OCT1 may be involved in mIBG liver uptake. The OCT2-MATEs pathway is believed to play a major role in active secretion of mIBG in the renal proximal tubule cells.

selectively increase gene transcription by opening the chromatin and making it more accessible to transcriptional factors (More et al., 2011). The use of vorinostat as a radiation sensitizer for ^{131}I-mIBG therapy has been recently explored in clinical studies with promising results (DuBois et al., 2015, 2021).

After gaining entry into tumor cells through NET, mIBG can be retained in the cytosol or further transported into intracellular organelles (Fig. 3A). For example, mIBG can be further taken up into secretory vesicles via the vesicular monoamine transporters 1 and 2 (VMAT1/2; *SLC27A1/2*). It was reported that in patients with high-risk metastatic neuroblastoma, VMAT1 and 2 were expressed in 62% and 75% of tumors, respectively (Temple et al., 2016). In addition, the expression level of VMAT2 but not that of VMAT1 correlated with avidity for mIBG in neuroblastoma (Temple et al., 2016). However, other studies suggested that only ∼7% of mIBG is contained in secretory vesicles in neuroblastoma cells (Lashford et al., 1991) and that the stimulation of vesicular release by calcium-dependent process and use of reserpine—a classic VMAT inhibitor—were demonstrated to have slight to no effect in mIBG retention in neuroblastoma cells (Smets et al., 1990; Servidei et al., 1995; Streby et al., 2015). Interestingly, in neuroblastoma the majority of mIBG appears to remain within the cytoplasm and is seemingly concentrated in the mitochondria through an unknown mechanism (Gaze et al., 1991; Lashford et al., 1991). In more differentiated neuroendocrine tumors such as pheochromocytoma and paragangliomas, intracellular mIBG is actively transported by VMAT1/2 after entering the cancer cells, leading to accumulation of mIBG in storage vesicles (Kölby et al., 2003). Such difference in intracellular disposition is possibly due to

neuroblastoma cells having fewer storage vesicles than more differentiated tumors (Smets et al., 1990; Montaldo et al., 1991; Streby et al., 2015).

The efflux of mIBG out of the cancer cells is thought to be through carrier-mediated efflux or by passive diffusion. In cultured neuroblastoma cell lines, efflux of mIBG was shown to be saturable, temperature-sensitive, and inducible by high extracellular potassium concentrations or the addition of norepinephrine or unlabeled mIBG (Servidei et al., 1995). This has led to the speculation that mIBG release from tumor cells efflux is mediated by a carrier, most likely NET working in a reverse mode. However, Lashford et al. (1991) suggested that after local release from the tumor cells, mIBG can undergo reuptake by NET and be transported back into cancer cells. Therefore, mIBG retention in cancer cells may depend on a dynamic equilibrium between active reuptake and efflux processes (Streby et al., 2015). Recently, Kobayashi et al. (2020) reported that mIBG is a substrate of multidrug resistance protein 1 and 4 (MRP1/4; *ABCC1/4*), which may contribute to the efflux of mIBG in neuroendocrine cancer cells. The clinical significance of the MRP transporters in ^{131}I-mIBG efficacy and treatment resistance has yet to be investigated.

mIBG Disposition in Normal Tissues and the Emerging Roles of Organic Cation Transporters

The distribution and accumulation of radioactive mIBG in normal tissues can complicate the findings from ^{123}I-mIBG imaging and the efficacy and safety of ^{131}I-mIBG radiotherapy for neuroendocrine cancers. Accumulation of ^{123}I-mIBG into normal tissues may interfere with tumor imaging, leading to an increased rate of false negatives for

TABLE 1

Characteristics of the monoamine and polyspecific organic cation transporters

Transporter (*Gene*)	mIBGK_m (μM)	Transport Mode	Tissue Distribution	References
NET (*SLC6A2*)	8.7 ± 1.4[a]	Cotransport with Na$^+$ & Cl$^-$	Central and peripheral noradrenergic neurons, adrenal medulla (chromaffin cells), lung, placenta	Wade et al., 1996; Eisenhofer, 2001; Torres et al., 2003; Wang et al., 2007; Blom et al., 2020; López Quiñones et al., 2020
DAT (*SLC6A3*)	N.D.	Cotransport with 2 Na$^+$ & Cl$^-$	Dopaminergic neurons, stomach, pancreas, kidney	
SERT (*SLC6A4*)	9.7 ± 1.4[b]	Cotransport with Na$^+$ & Cl$^-$	Serotoninergic neurons, platelets, gastrointestinal tract, placenta	
VMAT1 (*SLC27A1*)	N.D.	2H$^+$/monoamine exchange	Adrenal medulla (chromaffin cells), endocrine/paracrine cells associated with gastrointestinal tract	Weihe et al., 1994; Peter et al., 1995; Höltje et al., 2003; Wimalasena, 2011
VMAT2 (*SLC27A2*)	N.D.	2H$^+$/monoamine exchange	Adrenal medulla (chromaffin cells), neuronal cells in the central and peripheral nervous system, platelets	
OCT1 (*SLC22A1*)	19.5 ± 6.9[a]	Electrogenic	Liver, small intestine, adrenal glands	Koepsell, 2004; Wang et al., 2007; Giacomini et al., 2010; Lee et al., 2014; Wagner et al., 2016; Yin and Wang, 2016; López Quiñones et al., 2020
OCT2 (*SLC22A2*)	17.2 ± 2.8[a]	Electrogenic	Kidney, brain	
OCT3 (*SLC22A3*)	14.5 ± 7.1[a]	Electrogenic	Salivary glands, heart, placenta, skeletal muscle, brain, small intestine	
PMAT (*SLC29A4*)	N.D.	Electrogenic pH sensitive	Brain, kidney, small intestine, heart, liver, skeletal muscle	Engel et al., 2004; Dahlin et al., 2007; Xia et al., 2007; Zhou et al., 2007; Duan and Wang, 2013; Wagner et al., 2016; Wang, 2016; Vieira and Wang, 2021
MATE1 (*SLC47A1*)	17.7 ± 10.9[a]	Electroneutral (H$^+$/OC$^+$ exchange)	Kidney, liver, skeletal muscle	Otsuka et al., 2005; Masuda et al., 2006; Giacomini et al., 2010; Wagner et al., 2016; López Quiñones et al., 2020
MATE2/2-K (*SLC47A2*)	12.6 ± 5.6[a]	Electroneutral (H$^+$/OC$^+$ exchange)	Kidney	

DAT, dopamine transporter; N.D., not determined.

[a]Values obtained from (López Quiñones et al., 2020).

[b]Value obtained from (Blom et al., 2020).

diagnosing neuroendocrine cancers (Eisenhofer et al., 2003; Vik et al., 2009; Parisi et al., 2016). For therapeutic use, uptake of ^{131}I-mIBG into normal tissues can compete with tumor uptake, leading to reduced anti-tumor efficacy and increased tissue-specific toxicities. Importantly, the high uptake and accumulation in normal tissues are frequently associated with common and sometimes severe radiation-induced toxicities (Bleeker et al., 2013).

Compared with neuroendocrine cancer cells, much less is known on mIBG disposition in normal tissues. NET is predominantly expressed in neurons and neuroendocrine cells but is also expressed in the lung and thus may contribute to the pulmonary accumulation of mIBG (Torres et al., 2003). Although the closely related dopamine transporter (DAT; *SLC6A3*) and serotonin transporter (SERT; *SLC6A4*) (Table 1) were thought to not transport mIBG (Glowniak et al., 1993), recent evidence suggests that mIBG is a substrate of human SERT and that the transporter may contribute to the platelet accumulation of mIBG, which may lead to the common hematologic toxicities in ^{131}I-mIBG therapy (Blom et al., 2020).

Increasing evidence suggest that the polyspecific organic cation transporters play a major role in disposition of mIBG in normal tissues and organs. mIBG contains a guanidine moiety, which is a strong organic base (pKa of ~13) (Chen et al., 2019). Hence at physiologic pH, mIBG exists as an organic cation with limited passive permeability. The polyspecific organic cation transporters are a group of solute carriers that mediate the cellular uptake and efflux of structurally diverse organic cations. This group consists of the organic cation transporter 1–3 (OCT1–3; *SLC22A1–3*), the plasma membrane monoamine transporter (PMAT; *SLC29A4*), and the multidrug and toxin extrusion protein 1 and 2-K (MATE1/2-K; *SLC47A1/2*). The transport mediated by the OCTs and PMAT is electrogenic and sodium-independent (Table 1) (Koepsell, 2004; Wagner et al., 2016; Wang, 2016). On the other hand, transport by the MATEs is through an electroneutral exchange between an H$^+$ and a cationic substrate (Otsuka et al., 2005). The tissue

distribution and the general roles of OCTs and MATEs in drug disposition are well established (Table 1). In this section, we focus on discussing the roles that these transporters may play in systemic elimination and tissue-specific disposition of mIBG.

hOCT2/hMATEs in Renal Handling of mIBG. The renal handling of drugs is mainly governed by glomerular filtration, tubular secretion, and reabsorption. The tubular secretion of drugs is mediated by various drug transporters located in the basolateral and apical membranes of renal proximal tubular cells. The major organic cation transporters expressed in the human kidney are hOCT2 and hMATE1/2-K (Li et al., 2006; Morrissey et al., 2013; Yin and Wang, 2016) (Table 1). Organic cations in circulation are transported into renal tubular cells by the electrogenic hOCT2. The organic cations are then secreted into the renal lumen by hMATE 1 and 2-K, which are driven by the inwardly directed proton gradient (Li et al., 2006; Morrissey et al., 2013; Yin and Wang, 2016). Multiple cationic drugs (e.g., metformin, atenolol) undergo active secretion across the renal proximal tubule cells through the hOCT2 and hMATE1/2-K pathway (Giacomini et al., 2010; Yin and Wang, 2016).

mIBG is predominantly eliminated by the kidney, with more than 90% of the administered dose excreted unchanged in the urine (Lashford et al., 1988) (Fig. 2). Although the FDA labels for AdreView (^{123}I-mIBG) and Azedra (2018) (^{131}I-mIBG) only mention glomerulus filtration as a major process for renal elimination of mIBG, we have previously estimated a high contribution of tubular secretion using data from available pharmacokinetic studies (Ehninger et al., 1987; Blake et al., 1989; López Quiñones et al., 2020). In a cohort of patients with neuroblastoma, the renal clearance of mIBG was reported to be 226 ml/min with a mean glomerular filtration rate of 94 ml/min (Blake et al., 1989). Considering the plasma protein binding of mIBG (61%) as stated in the FDA label for Azedra (2018) (^{131}I-mIBG), the estimated glomerular filtration clearance is about 37 ml/min, which contributes to only

16% of the total renal clearance of mIBG. Thus, approximately 84% of the administered dose of mIBG is estimated to be eliminated through tubular secretion in the kidney.

We recently demonstrated that mIBG is efficiently transported by hOCT2, hMATE1, and hMATE2-K with apparent affinity (K_m) values of 17.2 ± 2.8, 17.7 ± 10.9, and 12.6 ± 5.6 μM, respectively, which are comparable to the K_m of hNET (8.7 ± 1.4 μM) under the same experimental condition (López Quiñones et al., 2020) (Table 1). Importantly, in hOCT2/hMATE1 double-transfected Madin-Darby canine kidney (MDCK) cells, mIBG was transported across the monolayer, with a higher permeability in the basal-to-apical direction than in the apical-to-basal direction and also when compared with control cells. These data suggest that hOCT2/hMATE1 in proximal tubule cells greatly facilitates the renal secretion of mIBG from the circulation into the renal lumen (Fig. 3B). Despite a substantial increase in basal-to-apical permeability, intracellular mIBG accumulation in hOCT2/hMATE1 cells was only marginally increased, suggesting that hOCT2-mediated uptake, but not hMATE-mediated efflux, is likely the rate-limiting step in the secretion process. In line with our observations, ^{123}I-mIBG whole-body imaging shows rapid and substantial bladder accumulation of ^{123}I-mIBG but only minimal to moderate kidney accumulation in patients with neuroblastoma and in healthy adults (Lashford et al., 1988; Chin et al., 2014).

The identification of the hOCT2-hMATE1/2-K pathway as the major route for systemic elimination of mIBG has important implications for the clinical use of mIBG because changes to the transport of mIBG by hOCT2 and/or hMATE could alter the pharmacokinetics and toxicity of radiolabeled mIBG. For instance, inhibition of the basolateral hOCT2 may reduce mIBG renal clearance, resulting in an increased systemic exposure that would result in greater radioactive exposure to the patients. Inhibition of hMATE-mediated efflux may increase intracellular accumulation of radioactive mIBG in proximal tubular cells, leading to increased risk of nephrotoxicity. The impact of hOCT2 and hMATE1/2-K on the pharmacokinetics and pharmacodynamics of ^{131}I-mIBG warrants further investigation. In particular, the drug interaction potentials with renal mIBG transporters should be considered during ^{131}I-mIBG therapy.

hOCT1 and hOCT3 in Tissue Uptake of mIBG. The liver, heart, salivary glands, and intestines are the major physiologic sites of high mIBG accumulation (Coleman et al., 2009; Chin et al., 2014). Consistently, cardiac, hepatic, and salivary gland toxicities have been observed with high-dose ^{131}I-mIBG therapy (Modak et al., 2008; Bleeker et al., 2013; Parisi et al., 2016). In humans, hOCT1 is predominantly expressed in the liver and localized to the sinusoidal membrane of hepatocytes (Giacomini et al., 2010). In addition, hOCT1 has been detected at low expression levels in other tissues, such as the adrenal gland and small intestine (Gorboulev et al., 1997; Koepsell, 2004; Wagner et al., 2016). mIBG is a substrate of OCT1 with a K_m value of 19.5 ± 6.9 μM as determined in HEK293 cells transfected with human OCT1 (López Quiñones et al., 2020). Although the liver is not a site for mIBG elimination, hepatic accumulation accounts for approximately 30% of the administered dose (Chin et al., 2014; Parisi et al., 2016). Using OCT1$^{-/-}$ mice, a 75% decrease was observed in the liver concentrations of mIBG 30 minutes after an intravenous injection, suggesting that OCT1 indeed contributes to the hepatic accumulation of mIBG in vivo (Jonker et al., 2001) (Fig. 3B). By selectively targeting OCT1 with a potent inhibitor, distribution of mIBG into the liver could be reduced, which may lead to improvements in the image resolution and toxicity profile of radioactive mIBG.

OCT3 is broadly expressed in various tissues, including salivary glands, heart, skeletal muscle, and placenta (Table 1). OCT3 is the major organic cation transporter expressed in both mouse and human salivary glands (Lee et al., 2014). OCT3 is localized on both the apical and basolateral membrane of the acinar cells lining the salivary glands, suggesting

that OCT3 is involved in both uptake into the salivary glands and secretion into saliva of organic cations. OCT3 expression in the heart is localized to vascular endothelial cells and myocardiocytes (Grube et al., 2011; Solbach et al., 2011). Using Oct3$^{-/-}$ mice, we previously demonstrated an important role of OCT3 in the uptake and transport of organic cationic drugs such as metformin and methamphetamine in salivary glands, skeletal muscle, and heart in vivo (Lee et al., 2014, 2018; Wagner et al., 2018). mIBG is efficiently transported by hOCT3 with a K_m value of 14.5 ± 7.1 μM that is comparable to hOCT1, hOCT2, and hMATE1/2-K (López Quiñones et al., 2020). These in vitro transport data alongside the tissue expression of OCT3 suggest that hOCT3 is an important determinant for mIBG uptake and accumulation in salivary glands and heart as illustrated in Fig. 3B. Bayer et al. (2016) previously proposed to improve tumor selective uptake of mIBG by reducing OCT3-mediated tissue uptake. In non–tumor-bearing mice, corticosteroids were shown to decrease mIBG uptake in a few tissues, including small intestine, kidney, and heart; whereas in a neuroblastoma patient dosed with hydrocortisone prior to ^{123}I-mIBG scan, liver and heart uptake of mIBG was reduced in comparison to other patients (Bayer et al., 2016). However, the nonselective inhibitory nature of corticosteroids makes it difficult to specifically interpret the impact of OCT3 on mIBG disposition in vivo. Our laboratory recently showed that crizotinib, a tyrosine kinase inhibitor used to treat neuroblastoma, preferentially inhibits hOCT3 (López Quiñones et al., 2020). Hence, crizotinib could be further explored to specifically block peripheral tissue uptake of ^{131}I-mIBG without affecting its systemic elimination or tumor uptake.

In addition to OCTs and MATEs, another polyspecific organic cation transporter, PMAT, was cloned and characterized by our laboratory (Engel et al., 2004). The transport of small organic cations by PMAT is electrogenic and pH sensitive (Duan and Wang, 2010; Zhou et al., 2010). PMAT is highly expressed in the brain and also has varied expression in the kidney, small intestine, and heart (Dahlin et al., 2007; Xia et al., 2007; Zhou et al., 2007; Duan and Wang, 2013; Vieira and Wang, 2021). Furthermore, PMAT was identified in an exploratory study as one of the top 25 membrane protein genes overexpressed in neuroblastoma tumor samples (Orentas et al., 2012). The role of PMAT in mIBG uptake in tumor and in normal tissue is currently under investigation in our laboratory.

Perspectives and Future Directions

Transporters on the plasma membrane of tumor cells are promising molecular "Trojan horses" to deliver drugs and imaging agents into cancer cells. Nevertheless, even with molecules designed to target tumor transporters, accumulation can still occur in normal tissues, raising concerns for tissue toxicity or decreased sensitivity in tumor detection. Although the same carrier transporting these agents into tumor cells may also contribute to their uptake in normal tissues, this is not always the case. As illustrated for mIBG in this review, tumor-targeting of this radiopharmaceutical is primarily mediated by NET expressed in neuroendocrine cancer cells, whereas its systemic elimination and accumulation in nontarget tissues are likely mediated by various polyspecific organic cation transporters (Fig. 3). Although the in vivo impact of various organic cation transporters in mIBG pharmacology remains to be validated through clinical studies, the prospect that tumor and normal cells employ a different set of transporters to transport mIBG is exciting and suggests a range of opportunities for future exploration to improve the clinical use of mIBG.

One obvious application is to selectively inhibit hOCT3 and/or hOCT1 to reduce ^{131}I-mIBG accumulation and toxicity in peripheral organs. As normal tissues also compete with tumor cells in mIBG uptake, one added advantage for this approach is that it may also

increase mIBG uptake in tumor cells. A critical challenge in this approach is to identify a highly specific inhibitor that does not interfere with either NET-mediated tumor uptake or hOCT2/hMATEs-mediated renal elimination. Similarly, enhancing NET expression in tumor cells (e.g., through the use of histone deacetylase inhibitor) is being explored clinically to increase ^{131}I-mIBG efficacy. For these endeavors, the effect of the NET enhancers on mIBG transporters in normal tissues should also be investigated, as changes in the expression and activity of these transporters could alter the disposition and toxicity of ^{131}I-mIBG.

The impact of hOCT2 and hMATE1/2-K on the pharmacokinetics and pharmacodynamics of mIBG warrants further investigation. In particular, the drug interaction potentials with renal mIBG transporters should be considered during ^{131}I-mIBG therapy. Patients with cancer often take multiple drugs to treat comorbidities, control pains, or relieve severe side effects associated with chemotherapy or radiation therapy. Thus, potential drug interactions at the transporter sites should be carefully considered. Currently, the use of clinical NET inhibitors such as tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors are avoided before and during mIBG imaging and therapy. Similarly, the potential impact of clinical inhibitors of hOCT2 and/or hMATE1/2-K should be considered. As tubular secretion of mIBG is the dominating pathway for systemic elimination of mIBG, blockage of this pathway may result in a change in ^{131}I-mIBG pharmacokinetics and pharmacodynamics. In particular, inhibition of hMATE-mediated efflux may increase intracellular accumulation of ^{131}I-mIBG in renal proximal tubule cells, leading to nephrotoxicity.

The discovery of mIBG as a substrate of polyspecific organic cation transporters also raises the possibility of using ^{123}I-mIBG as a radiotracer to image OCTs and MATEs activities in humans. When used as a diagnostic agent, ^{123}I-mIBG is given at a low dose, has a shorter radiation decay half-life, and emits low energy radiation. There are little radiation-associated toxicities for low dose ^{123}I-mIBG, suggesting that it may be used as a noninvasive imaging agent to detect changes in tissue expression or activities of hOCTs or hMATEs. Additionally, mIBG exhibits minimal metabolism and does not interact with adrenergic receptors. These characteristics are worth exploring in clinical drug-drug interaction (DDI) studies using ^{123}I-mIBG as a probe.

Conclusions

In this mini review, we discussed the clinical applications of mIBG and the roles of transporters as drivers of mIBG disposition, efficacy, and toxicity. Elucidating the transport mechanisms of mIBG in tumor and normal tissues has practical and translational values in the development of new clinical strategies to improve the diagnostic and therapeutic utility of radiolabeled mIBG. The clinical use of mIBG as a radiopharmaceutical in cancer diagnosis and treatment can be further improved by taking a holistic approach considering mIBG transporters in both cancer and normal tissues.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: López Quiñones, Vieira, Wang.

References

Ancey PB, Contat C, and Meylan E (2018) Glucose transporters in cancer - from tumor cells to the tumor microenvironment. *FEBS J* 285:2926–2943.

Anderson Jr GH, Blakeman N, and Streeten DH (1994) The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. *J Hypertens* 12:609–615.

Azedra (2018) Package insert. Progenics Pharmaceuticals, Inc., New York, NY.

Bayer M, Schmitt J, Dittmann H, Handgretinger R, Bruchelt G, and Sauter AW (2016) Improved selectivity of mIBG uptake into neuroblastoma cells in vitro and in vivo by inhibition of organic cation transporter 3 uptake using clinically approved corticosteroids. *Nucl Med Biol* 43:543–551.

Beierwaltes WH (1987) Update on basic research and clinical experience with metaiodobenzylguanidine. *Med Pediatr Oncol* 15:163–169.

Beierwaltes WH, Wieland DM, Yu T, Swanson DP, and Mosley ST (1978) Adrenal imaging agents: rationale, synthesis, formulation and, metabolism. *Semin Nucl Med* 8:5–21.

Biasotti S, Garaventa A, Villavecchia GP, Cabria M, Nantron M, and De Bernardi B (2000) False-negative metaiodobenzylguanidine scintigraphy at diagnosis of neuroblastoma. *Med Pediatr Oncol* 35:153–155.

Blake GM, Lewington VJ, Zivanovic MA, and Ackery DM (1989) Glomerular filtration rate and the kinetics of 123I-metaiodobenzylguanidine. *Eur J Nucl Med* 15:618–623.

Bleeker G, Schoot RA, Caron HN, de Kraker J, Hoefnagel CA, van Eck BL, and Tytgat GA (2013) Toxicity of upfront ^{131}I-metaiodobenzylguanidine (^{131}I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis. *Eur J Nucl Med Mol Imaging* 40:1711–1717.

Blom T, Meinsma R, Rutgers M, Buitenhuis C, Dekken-Van den Burg M, van Kuilenburg ABP, and Tytgat GAM (2020) Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake. *EJNMMI Res* 10:78.

Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, Board J, George RE, Ellershaw C, Pearson AD, et al. (2003) Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. *Clin Cancer Res* 9:3338–3344.

Chen W, Chang Y, Lee C, Liu S, Wu W, and Luo T (2019) Determination of impurities and degradation products/causes for m-iodobenzylguanidine using HPLC-tandem mass spectrometry. *Am J Analyt Chem* 10:590–607.

Chin BB, Kronauge JF, Femia FJ, Chen J, Maresca KP, Hillier S, Petry NA, James OG, Oldan JD, Armor T, et al. (2014) Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane. *J Nucl Med* 55:765–771.

Coleman RE, Stubbs JB, Barrett JA, de la Guardia M, Lafrance N, and Babich JW (2009) Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. *Cancer Biother Radiopharm* 24:469–475.

Dahlin A, Xia L, Kong W, Hevner R, and Wang J (2007) Expression and immunolocalization of the plasma membrane monoamine transporter in the brain. *Neuroscience* 146:1193–1211.

de Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, and Caron HN (2008) Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. *Eur J Cancer* 44:551–556.

Dhingra J and Halkar R (2020) I-131 MIBG therapy has been used as the first line therapy in pheochromocytoma. *J Nucl Med* 61:1452.

Duan H and Wang J (2010) Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. *J Pharmacol Exp Ther* 335:743–753.

Duan H and Wang J (2013) Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene. *J Biol Chem* 288:3535–3544.

Dubois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, Martinez D, Pawel B, Yanik G, Naranjo A, et al. (2012) Evaluation of norepinephrine transporter expression and metaiodobenzylguanidine avidity in neuroblastoma: a report from the Children's Oncology Group. *Int J Mol Imaging* 2012:250834.

DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, et al. (2021) Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report from NANT Consortium. *J Clin Oncol* 39:3506–3514.

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, et al. (2015) Phase I study of vorinostat as a radiation sensitizer with 131I-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma. *Clin Cancer Res* 21:2715–2721.

DuBois SG, Kalika Y, Lukens JN, Brodeur GM, Seeger RC, Atkinson JB, Haase GM, Black CT, Perez C, Shimada H, et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. *J Pediatr Hematol Oncol* 21:181–189.

Dutt M, Wehrle CJ, and Jialal I (2021) Physiology, adrenal gland, in *StatPearls*, StatPearls Publishing, Treasure Island, FL.

Ehninger G, Klingebiel T, Kumbier I, Schuler U, Feine U, Treuner J, and Waller HD (1987) Stability and pharmacokinetics of m-[131I]iodobenzylguanidine in patients. *Cancer Res* 47:6147–6149.

Eisenhofer G (2001) The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. *Pharmacol Ther* 91:35–62.

Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JWM, Keiser HR, and Pacak K (2003) Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. *J Clin Endocrinol Metab* 88:2656–2666.

Engel K, Zhou M, and Wang J (2004) Identification and characterization of a novel monoamine transporter in the human brain. *J Biol Chem* 279:50042–50049.

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, and Bray F (2020) *Global Cancer Observatory: Cancer Today*, International Agency for Research on Cancer, Lyon, France.

Fowler JS, Wolf AP, Christman DR, MacGregor RR, Ansari A, and Atkins H (1973) Carrier-free 11C-labeled catecholamines in nuclear medicine and biochemical research, in *Radiopharmaceuticals and Labelled Compounds*, International Atomic Energy Agency, Vienna, Austria.

Gaze MN, Huxham IM, Mairs RJ, and Barrett A (1991) Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging. *Int J Cancer* 47:875–880.

Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, and Turner FE (1993) Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. *J Nucl Med* 34:1140–1146.

Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, and Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. *DNA Cell Biol* 16:871–881.

Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C, and Pritchard J (1990) Skeletal assessment in neuroblastoma–the pitfalls of iodine-123-MIBG scans. *J Nucl Med* 31:129–134.

Graefe KH, Bossle F, Wölfel R, Burger A, Souladaki M, Bier D, Dutschka K, Farahati J, and Bönisch H (1999) Sympathomimetic effects of MIBG: comparison with tyramine. *J Nucl Med* **40**:1342–1351.

Grube M, Ameling S, Noutsias M, Köck K, Triebel I, Bonitz K, Meissner K, Jedlitschky G, Herda LR, Reinthaler M, et al. (2011) Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. *Am J Pathol* **178**:2547–2559.

Höltje M, Winter S, Walther D, Pahner I, Hörtnagl H, Ottersen OP, Bader M, and Ahnert-Hilger G (2003) The vesicular monoamine content regulates VMAT2 activity through Galphaq in mouse platelets. Evidence for autoregulation of vesicular transmitter uptake. *J Biol Chem* **278**:15850–15858.

Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. *Nat Rev Drug Discov* **9**:215–236.

Irwin MS and Park JR (2015) Neuroblastoma: paradigm for precision medicine. *Pediatr Clin North Am* **62**:225–256.

Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, and Mosse YP (2011) Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. *Pediatr Blood Cancer* **57**:1124–1129.

Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, and Schinkel AH (2001) Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. *Mol Cell Biol* **21**:5471–5477.

Kobayashi M, Mizutani A, Nishi K, Muranaka Y, Nishii R, Shikano N, Nakanishi T, Tamai I, Kleinerman ES, and Kawai K (2020) [131I]MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I]MIBG in neuroblastoma. *Nucl Med Biol* **90–91**:49–54.

Koepsell H (2004) Polyspecific organic cation transporters: their functions and interactions with drugs. *Trends Pharmacol Sci* **25**:375–381.

Kogai T and Brent GA (2012) The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. *Pharmacol Ther* **135**:355–370.

Kotecka-Blicharz A, Hasse-Lazar K, Handkiewicz-Junak D, Gawlik T, Pawlaczek A, Oczko-Wojciechowska M, Michalik B, Szpak-Ulczok S, Krajewska J, Jurecka-Lubieniecka B, et al. (2018) 131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study. *Endokrynol Pol* **69**:246–251.

Kölby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wängberg B, Ahlman H, Forssell-Aronsson E, and Nilsson O (2003) Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. *Br J Cancer* **89**:1383–1388.

Lam AK-Y (2017) Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. *Endocr Pathol* **28**:213–227.

Lashford LS, Hancock JP, and Kemshead JT (1991) Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C). *Int J Cancer* **47**:105–109.

Lashford LS, Moyes J, Ott R, Fielding S, Babich J, Mellors S, Gordon I, Evans K, and Kemshead JT (1988) The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma. *Eur J Nucl Med* **13**:574–577.

Lee N, Duan H, Hebert MF, Liang CJ, Rice KM, and Wang J (2014) Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. *J Biol Chem* **289**:27055–27064.

Lee N, Hebert MF, Wagner DJ, Easterling TR, Liang CJ, Rice K, and Wang J (2018) Organic cation transporter 3 facilitates fetal exposure to metformin during pregnancy. *Mol Pharmacol* **94**:1125–1131.

Lenders JW, Eisenhofer G, Mannelli M, and Pacak K (2005) Phaeochromocytoma. *Lancet* **366**:665–675.

Li M, Anderson GD, and Wang J (2006) Drug-drug interactions involving membrane transporters in the human kidney. *Expert Opin Drug Metab Toxicol* **2**:505–532.

Liu B, Zhuang H, and Servaes S (2013) Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors. *Q J Nucl Med Mol Imaging* **57**:21–28.

Lo CY, Lam KY, Wat MS, and Lam KS (2000) Adrenal pheochromocytoma remains a frequently overlooked diagnosis. *Am J Surg* **179**:212–215.

Loh K-C, Fitzgerald PA, Matthay KK, Yeo PPB, and Price DC (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. *J Endocrinol Invest* **20**:648–658.

López Quiñones AJ, Wagner DJ, and Wang J (2020) Characterization of *meta*-iodobenzylguanidine (mIBG) transport by polyspecific organic cation transporters: implication for mIBG therapy. *Mol Pharmacol* **98**:109–119.

Mairs RJ, Cunningham SH, Russell J, Armour A, Owens J, McKellar K, and Gaze MN (1995) No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. *J Nucl Med* **36**:1088–1095.

Mangner TJ, Tobes MC, Wieland DW, Sisson JC, and Shapiro B (1986) Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma. *J Nucl Med* **27**:37–44.

Maris JM, Hogarty MD, Bagatell R, and Cohn SL (2007) Neuroblastoma. *Lancet* **369**:2106–2120.

Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, and Inui K (2006) Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. *J Am Soc Nephrol* **17**:2127–2135.

Matthay KK, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V, Pearson ADJ, and Cohn SL (2010) Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. *Br J Cancer* **102**:1319–1326.

Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, et al. (2006) Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. *J Clin Oncol* **24**:500–506.

Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, et al.; Children's Cancer Group (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. *N Engl J Med* **341**:1165–1173.

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng S-C, Veatch J, Goldsby R, Brophy P, Kersun LS, et al. (2007) Phase II study on the effect of disease sites, age, and prior therapy

on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. *J Clin Oncol* **25**:1054–1060.

Modak S, Pandit-Taskar N, Kushner BH, Kramer K, Smith-Jones P, Larson S, and Cheung NK (2008) Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy. *Pediatr Blood Cancer* **50**:1271–1273.

Montaldo PG, Lanciotti M, Casalaro A, Cornaglia-Ferraris P, and Ponzoni M (1991) Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. *Cancer Res* **51**:4342–4346.

More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, Vanbrocklin HF, Weiss WA, Mueller S, Haas-Kogan DA, et al. (2011) Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. *Clin Cancer Res* **17**:2339–2349.

Morrissey KM, Stocker SL, Wittwer MB, Xu L, and Giacomini KM (2013) Renal transporters in drug development. *Annu Rev Pharmacol Toxicol* **53**:503–529.

Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, and Beierwaltes WH (1983) The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131] iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. *J Nucl Med* **24**: 672–682.

Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, and Kirste G (1993) Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. *N Engl J Med* **329**:1531–1538.

Nielsen JT, Nielsen BV, and Rehling M (1996) Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. *Clin Nucl Med* **21**:695–699.

Orentas JT, Yang JJ, Wen X, Wei JS, Mackall CL, and Khan J (2012) Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. *Front Oncol* **2**:194.

Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. *Proc Natl Acad Sci USA* **102**:17923–17928.

Parisi MT, Eslamy H, Park JR, Shulkin BL, and Yanik GA (2016) 131I-metaiodobenzylguanidine theranostics in neuroblastoma: historical perspectives; practical Applications. *Semin Nucl Med* **46**:184–202.

Parisi MT, Sandler ED, and Hattner RS (1992) The biodistribution of metaiodobenzylguanidine. *Semin Nucl Med* **22**:46–48.

Park JR, Eggert A, and Caron H (2008) Neuroblastoma: biology, prognosis, and treatment. *Pediatr Clin North Am* **55**:97–120.

Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, and Edwards RH (1995) Differential expression of two vesicular monoamine transporters. *J Neurosci* **15**:6179–6188.

Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, et al. (2019) Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. *J Nucl Med* **60**:623–630.

Rao D, van Berkel A, Piscaer I, Young WF, Gruber L, Deutschbein T, Fassnacht M, Beuschlein F, Spyroglou A, Prejbisz A, et al. 2019) Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma. *J Clin Endocrinol Metab* **104**:3812–3820.

Servidei T, Iavarone A, Lasorella A, Mastrangelo S, and Riccardi R (1995) Release mechanisms of [125I]meta-iodobenzylguanidine in neuroblastoma cells: evidence of a carrier-mediated efflux. *Eur J Cancer* **31A**:591–595.

Short JH and Darby TD (1967) Sympathetic nervous system blocking agents. 3. Derivatives of benzylguanidine. *J Med Chem* **10**:833–840.

Shusterman S, Grant FD, Lorenzen W, Davis RT, Laffin S, Drubach LA, Fahey FH, and Treves ST (2011) Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. *Semin Nucl Med* **41**:354–363.

Smets LA, Janssen M, Metwally E, and Loesberg C (1990) Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. *Biochem Pharmacol* **39**:1959–1964.

Solbach TF, Grube M, Fromm MF, and Zolk O (2011) Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization. *J Cardiovasc Pharmacol* **58**:409–417.

Streby KA, Shah N, Ranalli MA, Kunkler A, and Cripe TP (2015) Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. *Pediatr Blood Cancer* **62**:5–11.

Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, et al. (2016) Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. *Eur J Nucl Med Mol Imaging* **43**:474–481.

Torres GE, Gainetdinov RR, and Caron MG (2003) Plasma membrane monoamine transporters: structure, regulation and function. *Nat Rev Neurosci* **4**:13–25.

Treuner J, Gerein V, Klingebiel T, Schwabe D, Feine U, Happ J, Niethammer D, Maul F, Dopfer R, Kornhuber B, et al. (1988) MIBG-treatment in neuroblastoma; experiences at the Tübingen/Frankfurt group. *Prog Clin Biol Res* **271**:669–678.

van Santen HM, de Kraker J, van Eck BLF, de Vijlder JJM, and Vulsma T (2002) High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. *Cancer* **94**:2081–2089.

Vieira LS and Wang J (2021) Brain plasma membrane monoamine transporter in health and disease. *Handb Exp Pharmacol* **266**:253–280.

Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JCA, Heiba S, Serafini A, Tumeh S, Khutoryansky N, et al. (2009) (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. *Pediatr Blood Cancer* **52**:784–790.

Wade PR, Chen J, Jaffe B, Kassem IS, Blakely RD, and Gershon MD (1996) Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. *J Neurosci* **16**:2352–2364.

Wagner DJ, Hu T, and Wang J (2016) Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. *Pharmacol Res* **111**:237–246.

Wagner DJ, Shireman LM, Ahn S, Shen DD, and Wang J (2018) Disposition of methamphetamine and major metabolites in mice: role of organic cation transporter 3 in tissue-selective accumulation of *para*-hydroxymethamphetamine. *Drug Metab Dispos* **46**:1277–1284.

Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, Jinguji M, Shiga T, and Kinuya S (2019) A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. *Sci Rep* **9**:7625.

Wang J (2016) The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition. *Clin Pharmacol Ther* **100**:489–499.

Wang JS, Newport DJ, Stowe ZN, Donovan JL, Pennell PB, and DeVane CL (2007) The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. *Drug Metab Rev* **39**:723–746.

Ward E, DeSantis C, Robbins A, Kohler B, and Jemal A (2014) Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin* **64**:83–103.

Weihe E, Schäfer MK, Erickson JD, and Eiden LE (1994) Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. *J Mol Neurosci* **5**:149–164.

Wieland DM, Mangner TJ, Inbasekaran MN, Brown LE, and Wu JL (1984) Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. *J Med Chem* **27**:149–155.

Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, and Beierwaltes WH (1980) Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. *J Nucl Med* **21**:349–353.

Willenberg HS and Bornstein SR (2017) Adrenal cortex; development, anatomy, physiology, in *Endotext* [Internet] (Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Grossman A, Hershman JM, Hofland J, et al., eds) MDtext.com Inc., South Dartmouth, MA.

Wimalasena K (2011) Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. *Med Res Rev* **31**:483–519.

Wiseman GA, Pacak K, O'Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, Heiba SI, Serafini AN, Tumeh SS, Khutoryansky N, et al. (2009) Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. *J Nucl Med* **50**:1448–1454.

Xia L, Engel K, Zhou M, and Wang J (2007) Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. *Am J Physiol Renal Physiol* **292**:F682–F690.

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, et al. (2015) 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. *Biol Blood Marrow Transplant* **21**:673–681.

Yin J and Wang J (2016) Renal drug transporters and their significance in drug-drug interactions. *Acta Pharm Sin B* **6**:363–373.

Zhang Y and Wang J (2020) Targeting uptake transporters for cancer imaging and treatment. *Acta Pharm Sin B* **10**:79–90.

Zhou M, Engel K, Xia L, and Wang J (2010) Adenosine transport by plasma membrane monoamine transporter: reinvestigation and comparison with organic cations. *Drug Metab Dispos* **38**:1798–1805.

Zhou M, Xia L, and Wang J (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. *Drug Metab Dispos* **35**:1956–1962.

Address correspondence to: Dr. Joanne Wang, University of Washington, 1400 NE Campus Parkway, H272J Health Sciences Building, Seattle, WA 98195. E-mail: jowang@uw.edu